The role of tumor-associated macrophages in tumor vascularization

被引:80
作者
Guo, Chunqing [1 ]
Buranych, Annicole [1 ]
Sarkar, Devanand [1 ,2 ,3 ]
Fisher, Paul B. [1 ,2 ,3 ]
Wang, Xiang-Yang [1 ,2 ,3 ]
机构
[1] Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, POB 980033, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, VCU Inst Mol Med, Sch Med, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23298 USA
基金
美国国家卫生研究院;
关键词
Angiogenesis; Tumor vascularization; Tumor-associated macrophages;
D O I
10.1186/2045-824X-5-20
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Tumor vascularization is a highly complex process that involves the interaction between tumors and their surrounding stroma, as well as many distinct angiogenesis-regulating factors. Tumor associated macrophages (TAMs) represent one of the most abundant cell components in the tumor environment and key contributors to cancer-related inflammation. A large body of evidence supports the notion that TAMs play a critical role in promoting the formation of an abnormal tumor vascular network and subsequent tumor progression and invasion. Clinical and experimental evidence has shown that high levels of infiltrating TAMs are associated with poor patient prognosis and tumor resistance to therapies. In addition to stimulating angiogenesis during tumor growth, TAMs enhance tumor revascularization in response to cytotoxic therapy (e.g., radiotherapy), thereby causing cancer relapse. In this review, we highlight the emerging data related to the phenotype and polarization of TAMs in the tumor microenvironment, as well as the underlying mechanisms of macrophage function in the regulation of the angiogenic switch and tumor vascularization. Additionally, we discuss the potential of targeting pro-angiogenic TAMs, or reprograming TAMs toward a tumoricidal and angiostatic phenotype, to promote normalization of the tumor vasculature to enhance the outcome of cancer therapies.
引用
收藏
页数:12
相关论文
共 155 条
[11]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[12]   Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[13]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[14]   The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].
Bingle, L ;
Brown, NJ ;
Lewis, CE .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265
[15]   A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation) [J].
Biswas, SK ;
Gangi, L ;
Paul, S ;
Schioppa, T ;
Saccani, A ;
Sironi, M ;
Bottazzi, B ;
Doni, A ;
Vincenzo, B ;
Pasqualini, F ;
Vago, L ;
Nebuloni, M ;
Mantovani, A ;
Sica, A .
BLOOD, 2006, 107 (05) :2112-2122
[16]   PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties [J].
Bouhlel, M. Amine ;
Derudas, Bruno ;
Rigamonti, Elena ;
Dievart, Rebecca ;
Brozek, John ;
Haulon, Stephan ;
Zawadzki, Christophe ;
Jude, Brigitte ;
Torpier, Gerard ;
Marx, Nikolaus ;
Staels, Bart ;
Chinetti-Gbaguidi, Giulia .
CELL METABOLISM, 2007, 6 (02) :137-143
[17]   Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2 [J].
Brecht, Kerstin ;
Weigert, Andreas ;
Hu, Jiong ;
Popp, Ruediger ;
Fisslthaler, Beate ;
Korff, Thomas ;
Fleming, Ingrid ;
Geisslinger, Gerd ;
Bruene, Bernhard .
FASEB JOURNAL, 2011, 25 (07) :2408-2417
[18]   Angiogenesis in health and disease [J].
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (06) :653-660
[19]   Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases [J].
Carmeliet, Peter ;
Jain, Rakesh K. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) :417-427
[20]   Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 [J].
Ceradini, DJ ;
Kulkarni, AR ;
Callaghan, MJ ;
Tepper, OM ;
Bastidas, N ;
Kleinman, ME ;
Capla, JM ;
Galiano, RD ;
Levine, JP ;
Gurtner, GC .
NATURE MEDICINE, 2004, 10 (08) :858-864